Comparative evaluation and preference of MixPro® versus Mix2Vial® reconstitution devices among people with haemophilia and caregivers
Article Category: Clinical Research
Online veröffentlicht: 08. Okt. 2022
Seitenbereich: 103 - 117
DOI: https://doi.org/10.2478/jhp-2022-0012
Schlüsselwörter
© 2022 Jon Ulrich Hansen et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Introduction
People with haemophilia (PwH) require frequent infusions with plasma-derived or recombinant coagulation factors to help prevent and treat acute bleeding episodes. This ‘replacement therapy’ can be administered at home by PwH or their caregivers using a drug reconstitution device. MixPro® and Mix2Vial® are two such devices.
Aims/Objectives
To compare the experiences and evaluate the preferences of PwH and caregivers using two reconstitution devices: MixPro® and Mix2Vial®.
Methods
Qualitative interviews were conducted between the 22 June and 4 August 2021 with male PwH or caregivers of PwH. Participants were asked questions about the reconstitution devices they have used in general, followed by questions relating specifically to the MixPro® or Mix2Vial® devices. Demonstration devices were provided to all participants during the interview.
Results
In total, 105 participants (71 PwH and 34 caregivers) were interviewed in the USA, Italy, UK, and Japan. PwH had a mean age of 29 years (3–69 years). Overall, participants reported the number of parts, speed of reconstitution, and ease of use to be the largest unmet needs with reconstitution devices. Regarding the device features,
Conclusion
In this study, MixPro® was preferred over Mix2Vial® as a reconstitution device for PwH and caregivers of PwH.